ATE229034T1 - 3-mercaptoacetylamino-1,5-substituierte-2-oxo- azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen - Google Patents

3-mercaptoacetylamino-1,5-substituierte-2-oxo- azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen

Info

Publication number
ATE229034T1
ATE229034T1 AT97935308T AT97935308T ATE229034T1 AT E229034 T1 ATE229034 T1 AT E229034T1 AT 97935308 T AT97935308 T AT 97935308T AT 97935308 T AT97935308 T AT 97935308T AT E229034 T1 ATE229034 T1 AT E229034T1
Authority
AT
Austria
Prior art keywords
mercaptoacetylamino
oxo
inhibitors
substituted
matrix metalloproteinases
Prior art date
Application number
AT97935308T
Other languages
English (en)
Inventor
Alan M Warshawsky
Gary A Flynn
Meena V Patel
Douglas W Beight
Joseph P Burkhart
Jiu-Tsair Tsay
Michael J Janusz
Jian Shen
Ramalinga M Dharanipragada
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE229034T1 publication Critical patent/ATE229034T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT97935308T 1996-09-19 1997-08-04 3-mercaptoacetylamino-1,5-substituierte-2-oxo- azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen ATE229034T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71929196A 1996-09-19 1996-09-19
PCT/US1997/013738 WO1998012211A1 (en) 1996-09-19 1997-08-04 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase

Publications (1)

Publication Number Publication Date
ATE229034T1 true ATE229034T1 (de) 2002-12-15

Family

ID=24889504

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97935308T ATE229034T1 (de) 1996-09-19 1997-08-04 3-mercaptoacetylamino-1,5-substituierte-2-oxo- azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen

Country Status (21)

Country Link
EP (1) EP0928291B1 (de)
JP (1) JP3962091B2 (de)
KR (1) KR100545460B1 (de)
CN (1) CN1150205C (de)
AR (1) AR009363A1 (de)
AT (1) ATE229034T1 (de)
AU (1) AU718055B2 (de)
BR (1) BR9713207A (de)
CA (1) CA2266759C (de)
DE (1) DE69717647T2 (de)
DK (1) DK0928291T3 (de)
ES (1) ES2184126T3 (de)
HK (1) HK1020741A1 (de)
HU (1) HUP9904165A3 (de)
IL (2) IL129035A0 (de)
NO (1) NO991316L (de)
NZ (1) NZ334490A (de)
PT (1) PT928291E (de)
TW (1) TW445262B (de)
WO (1) WO1998012211A1 (de)
ZA (1) ZA978307B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1817700A (en) * 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6486193B2 (en) 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
US6770640B1 (en) 1998-12-31 2004-08-03 Aventis Pharmaceuticals Inc. 1-Carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of MMP-12
AU1926500A (en) * 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metallo-proteinases
CA2360305A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company Lactam inhibitors of fxa and method
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
JP2003513972A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
AU1474801A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
WO2001034599A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
SK13632002A3 (sk) 2000-03-21 2003-02-04 Smithkline Beecham Corporation C1-6-alkyl-4-amino-azepán-3-ónové zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
US7704521B2 (en) 2007-04-11 2010-04-27 Zinpro Corporation Rumen protected essential amino acids
US20080255234A1 (en) * 2007-04-11 2008-10-16 Zinpro Corporation Rumen protected lysine
WO2018220032A1 (en) 2017-05-31 2018-12-06 B.R.A.I.N. Biotechnology Research And Information Network Ag Optimization of the expression of serine proteases in host cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006890A1 (en) * 1987-03-17 1988-09-22 Research Corporation Technologies, Inc. Synthetic inhibitors of mammalian collagenase
JPH07304746A (ja) * 1994-05-11 1995-11-21 Kanebo Ltd 新規ベンゾアゼピンカルボン酸誘導体
MX9702487A (es) * 1994-10-05 1998-04-30 Darwin Discovery Ltd Compuestos peptidilo y su uso terapeutico como inhibidores de las metaloproteasas.
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids

Also Published As

Publication number Publication date
EP0928291A1 (de) 1999-07-14
HK1020741A1 (en) 2000-05-19
EP0928291B1 (de) 2002-12-04
AU718055B2 (en) 2000-04-06
NO991316D0 (no) 1999-03-18
WO1998012211A1 (en) 1998-03-26
HUP9904165A2 (hu) 2000-03-28
NZ334490A (en) 2000-08-25
NO991316L (no) 1999-05-18
ES2184126T3 (es) 2003-04-01
IL129035A0 (en) 2000-02-17
HUP9904165A3 (en) 2002-01-28
DE69717647T2 (de) 2003-09-25
KR100545460B1 (ko) 2006-01-24
JP2001501926A (ja) 2001-02-13
CA2266759A1 (en) 1998-03-26
JP3962091B2 (ja) 2007-08-22
IL129035A (en) 2006-12-10
ZA978307B (en) 1998-03-19
AU3827897A (en) 1998-04-14
CN1150205C (zh) 2004-05-19
BR9713207A (pt) 2000-04-04
DE69717647D1 (de) 2003-01-16
PT928291E (pt) 2003-03-31
CA2266759C (en) 2004-10-26
CN1234039A (zh) 1999-11-03
AR009363A1 (es) 2000-04-12
DK0928291T3 (da) 2003-03-17
TW445262B (en) 2001-07-11
KR20000036246A (ko) 2000-06-26

Similar Documents

Publication Publication Date Title
ATE248143T1 (de) Carnamoyloxy derivate von mutilin und deren verwendung als antibakterielles mittels
ATE277895T1 (de) 4-brom or 4-iod-phenylamino- benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
ATE248150T1 (de) Lactam-enthaltende hydroxamsäure-derivate, deren herstellung und deren verwendung als inhibitoren von matrix-metalloproteasen
DE69407561T2 (de) Harnstoff Derivate und deren Verwendung als ACAT Inhibitoren
DE69736994D1 (de) Ionische Malonsäuredinitril Derivate und deren Verwendung
DE59913617D1 (de) Indolderivate und deren Verwendung als Inhibitoren der Phosphodiesterase 4.
DE59803292D1 (de) Triazolverbindungen und deren verwendung als dopamin-d 3-liganden
DE69734149D1 (de) Cinoline derivate und verwendung als heilmittel
DE69720194D1 (de) Piperazinonphenyloxazolidinon derivate und ihre verwendung als antibakterielle mittel
DE69529849D1 (de) Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6-yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
ATE231883T1 (de) Neuartige aminosäurederivate und deren verwendung als thrombininhibitoren
ATE224910T1 (de) Derivate von dolestatin, deren herstellung und verwendung
ATE229034T1 (de) 3-mercaptoacetylamino-1,5-substituierte-2-oxo- azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen
ATE277902T1 (de) Amidinoderivate und ihre verwendung als thrombininhibitoren
DE3774858D1 (de) Derivate von n-(2-alkyl-3-mercaptoglutaryl)-alpha-aminosaeuren und deren verwendung als collagenase-inhibitoren.
DE69708629D1 (de) Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren
DE60005300D1 (de) 2,3-o-isoproylidene derivativen von monosacchariden und verwendung als zell-adhäsion-inhibitoren
DE69821988D1 (de) Substituierte isochinoline derivate und ihre verwendung als anticonvulsiva
DE69514120D1 (de) Derivate von o-benzyl-oxin-ether sowie deren verwendung als pestizide
DE69831427D1 (de) Benzo(c)quinolizinderivative und deren verwendung als 5 alpha-reduktase-hemmer
ATE228372T1 (de) Hcg und derivate als matrixmetalloprotease- inhibitoren
DE69718850D1 (de) Heterocyclische N-Acetonylbenzamide und ihre Verwendung als Fungizide
DE69318036T2 (de) Arylamino-alkoximino derivate und deren verwendung als fungizide
DE69707602D1 (de) Substituierte Vinylharnstoff-Derivate und ihre Verwendung als ACAT-Inhibitoren
ATE218343T1 (de) Verwendung von substituierten und nichtsubstituierten n-(pyrrol-1-yl)pyridinaminen als antikonvulsiva

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0928291

Country of ref document: EP

EEIH Change in the person of patent owner